Integration of serum androgens and Sex Hormone-Binding Globulin for optimized early detection of aggressive prostate cancer

Olga Lazareva; Anja Riediger; Oliver Stegle; Holger Sültmann; Markus Hohenfellner; Magdalena Görtz

doi:10.1101/2024.12.05.24318544

ABSTRACT

Background Aggressive prostate cancer (PC) represents a significant health concern worldwide. Conventional initial screening methods, primarily based on prostate-specific antigen (PSA) levels, lack specificity, leading to a high rate of unnecessary biopsies and an urgent need for more accurate diagnostic tools. This study addresses the gap by exploring the potential of integrating clinical and routine blood laboratory parameters including a comprehensive hormone assessment to enhance the non-invasive prediction of aggressive PC.

Methods In a pilot study of 578 patients who were scheduled for a prostate biopsy due to suspicion of PC, we analyzed an extensive panel of 28 laboratory values alongside data on family history, diet, and lifestyle. A logistic regression classifier was developed, and model performance was evaluated using repeated k-fold cross-validation on the complete dataset (n=282). Participants were histologically categorized into three risk groups: healthy, moderate PC (ISUP 1-2 PC), and aggressive PC (ISUP 3-5 PC).

Results Significant associations were found between PC aggressiveness and lower levels of androstenedione, Dehydroepiandrosterone-Sulfate (DHEA-S) and free PSA percentage, as well as higher levels of Sex Hormone Binding Globulin (SHBG). The integration of these serum markers with clinical parameters into a new multi-stage risk classifier for PC prediction significantly improved the predictive accuracy. The risk model outperformed PSA-only methods, demonstrating higher sensitivity and specificity in predicting aggressive PC.

Conclusions Incorporating serum markers DHEA-S, androstenedione, and SHBG into a novel risk classifier can improve early detection of aggressive PC. These widely available and cost-effective blood biomarkers could reduce reliance on invasive prostate biopsies and expensive magnetic resonance imaging by providing a more targeted approach to non-invasive prediction of aggressive PC following PSA testing. Our pilot study lays the groundwork for larger-scale research to further explore the integration of androgens and SHBG in future risk stratification models for improved clinical decision making.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by the German Federal Ministry for Economic Affairs and Climate Action (funding # 01MT21004A) and the Dieter Morszeck Foundation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The ethical committee of the University of Heidelberg gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes